✦ LIBER ✦

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy

✍ Scribed by Nazik HAMMAD; Lance K HEILBRUN; Philip A PHILIP; Anthony F SHIELDS; Mark M ZALUPSKI; Raghu VENKATRAMANAMOORTHY; Bassel F EL-RAYES

Book ID: 111318815
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 225 KB
Volume: 6
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2010.01290.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pretreatment CA 19-9 Level as a Prognost

Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine

✍ Saad, Everardo D. ;Machado, Marcel C. ;Wajsbrot, Dalia ;Abramoff, Roberto ;Hoff, 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 88 KB

Relationship of tumor response and survi

Relationship of tumor response and survival in advanced ovarian cancer patients treated with chemotherapy

✍ Valter Torri; Richard Simon; Estelle Russek-Cohen; Douglas Midthune; Michael Fri 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 77 KB

CA19-9 as a predictor of recurrence in p

CA19-9 as a predictor of recurrence in patients with colorectal cancer

✍ Nakayama, Takamori; Watanabe, Masahiko; Teramoto, Tatsuo; Kitajima, Masaki 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Background and Objectives: CA19-9 is a cancer-associated carbohydrate antigen that plays a role in the process of tumor progression as an adhesion molecule. Methods: We evaluated the prognostic value of CA19-9 tumor expression and CA19-9 preoperative and postoperative serum levels in colorectal canc

CA 19-9 tumour-marker response to chemot

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

✍ Viviane Hess; Bengt Glimelius; Philipp Grawe; Daniel Dietrich; György Bodoky; Th 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 186 KB

Serum CA 19-9 as a Marker of Resectabili

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

✍ Matthew H. G. Katz; Gauri R. Varadhachary; Jason B. Fleming; Robert A. Wolff; Je 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 326 KB

Estimating prognosis and palliation base

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

✍ Bernhard, J; Dietrich, D; Glimelius, B; Hess, V; Bodoky, G; Scheithauer, W; Herr 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 371 KB